Novartis AG (NVS)
| Market Cap | 208.59B |
| Revenue (ttm) | 52.32B |
| Net Income (ttm) | 7.84B |
| Shares Out | 2.07B |
| EPS (ttm) | 3.73 |
| PE Ratio | 26.16 |
| Forward PE | 14.35 |
| Dividend | $3.47 (3.44%) |
| Ex-Dividend Date | Mar 9, 2023 |
| Volume | 956,698 |
| Open | 100.34 |
| Previous Close | 99.97 |
| Day's Range | 100.34 - 101.04 |
| 52-Week Range | 79.98 - 105.61 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Jan 31, 2024 |
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated ... [Read more]
Financial Performance
In 2022, Novartis AG's revenue was $51.83 billion, a decrease of -1.98% compared to the previous year's $52.88 billion. Earnings were $6.96 billion, a decrease of -71.05%.
Financial StatementsNews
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs.
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 ...
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
Basel, December 8, 2023 – Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months...
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH, patien...
Novartis aims for 5% annual sales growth through 2027
Novartis said it was targeting annual sales growth of 5% per year until 2027 and a core operating income margin of about 40% by 2027, driven by innovative drugs on the market, after it severed ownersh...
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play' innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth Mid-t...
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Basel, November 20, 2023 — Novartis will present data from over 100 trials across its breast cancer and hematology portfolios at the 2023 San Antonio Breast Cancer Symposium (SABCS) and the American S...
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
Basel, November 9, 2023 — Novartis today announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib – a highly selective, oral Bruton's tyrosine kinase (BTK)...
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Basel, October 31, 2023 — Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat...
Novartis says drug candidate is successful in rare kidney disease trial
Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug...
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs.
Novartis Raises Outlook After Sandoz Generics Spinoff
Novartis CEO Vas Narasimhan discusses third-quarter results with the company lifting its profit forecast for a third time as he calls the drugmaker a pure-play innovative medicines “powerhouse.” He sp...
Novartis Begins New Era With Profit Beat and Guidance Hike
The Swiss pharmaceutical company says its transition to a pure-play innovative medicines business is now complete following the spinoff of Sandoz, its generic drugs unit.
Novartis lifts 2023 earnings forecast for third time
Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun off and listed on Oct 4.
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing operations 2 Q 3 ...
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
Basel, October 23, 2023 — Novartis today presents data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium...
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Basel, October 20, 2023 — Novartis will present late-breaking results from a prespecified exploratory subgroup analysis of invasive disease-free survival (iDFS) from the pivotal Phase III NATALEE tria...
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Although healthcare stocks lag other sectors, large-cap leaders such as Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS are in possible buy ranges as they get moving-av...
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Basel, October 5, 2023 — Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developme...
Novartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines company
Novartis CEO Vas Narasimhan discusses what the spinoff of the company's Sandoz unit means for the organization.
Novartis unit Sandoz set to start trading after completing spinoff
Novartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.
Novartis completes Sandoz spinoff
Novartis has completed the planned spin-off of its generics and biosimilars business Sandoz , the Swiss drugmaker said in a statement on Wednesday.
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
Basel, October 4, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company.
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off Shares of Sandoz will be listed and commence ...
Novartis positioning is now best-suited for long-term gains and returns after spin-off, says CEO
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's gr...